NEOGENOMICS INC — Director's Dealing 2014

Aug 18, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2014-04-15

Reporting Person: VAN OORT DOUGLAS M (Director, Chairman and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-04-15	Common Stock	A	125000	$3.05	Acquired	133600	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	991456	Indirect
Common Stock	187500	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to buy)	$1.71	2017-02-14	Common Stock (0)	800000	Direct
Stock Option (Right to buy)	$0.8	2016-03-15	Common Stock (0)	1000000	Direct

Footnotes

F1: On April 15, 2014 the Board of Directors approved and granted a restricted stock award of 125,000 shares of NeoGenomics common stock to Mr. VanOort. The terms of the award call for the stock to vest on the third anniversary of the grant date as long as Mr. VanOort is still an employee of the Company. This was disclosed in our Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission on July 29, 2014.

F2: Conundrum Capital Partners, LLC is a limited partnership 50% owned by Mr. VanOort. Mr. VanOort is a managing partner of Condundrum Capital Partners, LLC.

F3: On February 14, 2012 Mr. VanOort was granted options to purchase 800,000 shares. These shares vest equally over each of the first four anniversaries of the grant date.

F4: On March 15, 2009 Mr. VanOort was granted options to purchase 1,000,000 shares. The grant was comprised of 500,000 time based options and 500,000 performance based options. The first date that vesting became available was December 31, 2009.